What is Regenxbio's software and technology licenses, net?

Regenxbio (RGNX) reported software and technology licenses, net of $5.51M in Q1 2026.

How has Regenxbio's software and technology licenses, net changed year-over-year?

Regenxbio's software and technology licenses, net increased by 84.6% year-over-year, from $2.99M to $5.51M.

What is the long-term trend for Regenxbio's software and technology licenses, net?

Over 5 years (2020 to 2025), Regenxbio's software and technology licenses, net has grown at a -2.7% compound annual growth rate (CAGR), from $5.28M to $4.61M.

Regenxbio RGNX Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Regeneron PharmaceuticalsREGN

——

Sarepta Therapeutics, Inc.SRPT

——

BiogenBIIB

——

BioMarin PharmaceuticalsBMRN

——

EyePoint, Inc. EYPT

——

Ultragenyx PharmaceuticalRARE

——

Other financials

Income statement

See full

Revenue$6.4M-92.8%

Gross profit$14.9M+35.7%

Operating income-$83.4M-787%

Net income-$90.1M-1,580%

EPS (diluted)-$1.72-1,533%

Balance sheet

See full

Cash & equivalents$15.2M-88.3%

Total debt$71.1M-11.0%

Total equity$21.1M-92.3%

Total assets$341.9M-30.4%

Cash flow

See full

Operating cash flow-$76.2M-327%

CapEx$1.2M+20.6%

Free cash flow-$77.4M-337%

Valuation

See full

Market cap$529.38M+24.6%

Enterprise value$585.22M+56.3%

P/S6×+3.3×

Profitability

See full

Gross margin59.7%+1.0pp

Operating margin-292.3%-613pp

Net margin-330.2%-588pp

FCF margin-269.2%-364pp

Returns & leverage

See full

Return on equity-196.4%-288pp

Debt / equity3.4×+3.1×

Current ratio2.6×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Regenxbio's software and technology licenses, net?: Regenxbio (RGNX) reported software and technology licenses, net of $5.51M in Q1 2026.
How has Regenxbio's software and technology licenses, net changed year-over-year?: Regenxbio's software and technology licenses, net increased by 84.6% year-over-year, from $2.99M to $5.51M.
What is the long-term trend for Regenxbio's software and technology licenses, net?: Over 5 years (2020 to 2025), Regenxbio's software and technology licenses, net has grown at a -2.7% compound annual growth rate (CAGR), from $5.28M to $4.61M.